THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION.

PUBLICATION RELATING TO A TRANSPARENCY NOTIFICATION

(ARTICLE 14, 1ST PARAGRAPH, OF THE LAW OF 2 MAY 2007 ON THE DISCLOSURE OF MAJOR HOLDINGS)

Acacia Pharma Group plc

 1.     Summary of the notification

Cambridge, UK and Indianapolis, US – 26 February 2021, 08:00 CET: Acacia Pharma Group plc has received a transparency notification dated 23 February 2021 indicating that Cosmo Pharmaceuticals N.V now holds, by virtue of the issue of shares on 23 February 2021, 19.66% of the voting rights of the company. Cosmo has therefore crossed the threshold of 20%.

2.     Content of notification
The notification dated 23 February 2021 contains the following information:

A)     Voting rightsPrevious notificationAfter the transaction
 # of voting rights# of voting rights% of voting rights
Holders of voting rights Linked to securitiesNot linked to securitiesLinked to securitiesNot linked to securities
Cosmo Pharmaceuticals N.V.0000.00%0.00%
Cosmo Technologies Ltd.19,600,09819,600,098019.66%0.00%
Subtotal19,600,09819,600,098 19.66% 
 TOTAL19,600,098019.66%0.00%


B)     Voting rightsAfter the transaction
Holders of equivalent financial instrumentsType of financial instrumentExpiration dateExercise period or date# of voting rights that may be acquired if the instrument is exercised% of voting rightsSettlement
       
 TOTAL  00.00% 
       
 TOTAL (A+B)  # of voting rights% of voting rights 
   CALCULATE19,600,09819.66% 

      ·Full chain of controlled undertakings through which the holding is effectively held: Cosmo Technologies Ltd is a 100% subsidiary of Cosmo Pharmaceuticals N.V.

  1. Miscellaneous

    Contacts

    Acacia Pharma Group plc
    Mike Bolinder, CEO
    Gary Gemignani, CFO
    +44 1223 919760 / +1 317 505 1280
    IR@acaciapharma.com

         		International Media
    Mark Swallow, Frazer Hall, David Dible
    Citigate Dewe Rogerson
    +44 20 7638 9571
    acaciapharma@citigatedewerogerson.com
    US Investors
    LifeSci Advisors
    Irina Koffler
    +1 917-734-7387
    ikoffler@lifesciadvisors.com    		Media in Belgium and the Netherlands
    Chris Van Raemdonck
    +32 499 58 55 31
    chrisvanraemdonck@telenet.be

    Acacia Pharma Group plc
    The Officers’ Mess, Royston Road, Duxford, Cambridge, CB22 4QH, United Kingdom
    Company number 9759376

    About Acacia Pharma

    Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures, or cancer chemotherapy. The Company has identified important and commercially attractive unmet needs in these areas that its product portfolio aims to address.

    Acacia Pharma's first product, BARHEMSYS® (amisulpride injection) is marketed in the US for the management of postoperative nausea & vomiting (PONV).

    BYFAVO™ (remimazolam) for injection, a very rapid onset/offset IV benzodiazepine sedative is approved and launched in the US for use during invasive medical procedures in adults lasting 30 minutes or less, such as colonoscopy and bronchoscopy. BYFAVO is in-licensed from Paion UK Limited for the US market.

    APD403 (intravenous and oral amisulpride), a selective dopamine antagonist for chemotherapy induced nausea & vomiting (CINV) has successfully completed one proof-of-concept and one Phase 2 dose-ranging study in patients receiving highly emetogenic chemotherapy.

    Acacia Pharma has its US headquarters in Indianapolis, IN and its R&D operations are centered in Cambridge, UK. The Company is listed on the Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker symbol ACPH.

    www.acaciapharma.com

    Attachment